MacroGenics, Inc. (MGNX) - Quarterly EPS earnings growth

Brandmark of MacroGenics, Inc. (MGNX)

Quarterly EPS progress demonstrates the profit dynamics of MacroGenics, Inc. (MGNX), where -226.60 characterizes this valuation parameter. Current innovation expenses are outpacing revenues, but a liquid reserve supports operations. Antibody production is combined with the engagement of external partners for trials. Meanwhile, MacroGenics, Inc. (MGNX) strictly adheres to environmental standards, minimizing laboratory emissions and optimizing transport flows.

MacroGenics (MGNX) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company MacroGenics, Inc. (MGNX)

- market value and analyst target forecast:
Price Chart MacroGenics, Inc.|MGNX - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization MacroGenics, Inc.|MGNX - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share MacroGenics|MGNX - Total Stockholders' Equity|Market Value to Book Value Ratio macrogenics.com|MGNX - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity MacroGenics, Inc.|MGNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital macrogenics.com|MGNX - Company Aggregate Debts|Debts to Book Capitalization MacroGenics, Inc.|MGNX - Company Long-Term Liabilities|Company Short-Term Debt MacroGenics|Quick Liquidity macrogenics.com
- earnings and valuation multiples indicators:
MGNX - Company Net Income|Projected Future Earnings MacroGenics, Inc.|MGNX - Market Cap to Net Income Ratio|Forward P/E Multiple MacroGenics Inc|MGNX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MacroGenics Inc|MGNX - Operating profit before amortization|Net earnings per share (EPS TTM) MacroGenics|MGNX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth macrogenics.com|MGNX - Net earnings per share growth this year|Net earnings per share growth forecast for next year MacroGenics, Inc.
- sales volume and revenue indicators:
MGNX - Company Gross Revenue|Company Future Sales Volume MacroGenics Corp|MGNX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple MacroGenics Inc
Initial company analysis:MacroGenics Inc. - MGNX
Manufactured product of MacroGenics Inc.

This indicator measures the percentage change in earnings per share between the current and corresponding previous quarter, allowing for an assessment of the real profitability dynamics of MacroGenics, Inc. (MGNX). By analyzing the quarterly EPS growth trend, an investor can see the impact of licensing payments and the success of the DART platform, where profit growth rates confirm the commercial efficiency of developing drugs against metastatic cancer.

Main competitors

Olema Pharmaceuticals (OLMA) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months PBYI|GLSI (greenwichlifesciences.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Zentalis Pharmaceuticals (ZNTL)|Quarterly EPS earnings growth PSTV|PCSA - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Eagle Pharmaceuticals EGRX